Oral COVID-19 vaccine being tested
(HealthDay)—California researchers are testing whether an oral vaccine offers similar or better protection than current COVID-19 shots.
Existing vaccines promote production of antibodies to the spike protein on the surface of the coronavirus that causes COVID-19, but the ImmunityBio T cell oral vaccine targets the globe in the middle of the virus, a part that is less prone to mutation, according to scientists. "And the value of doing so is that we generate killer T cells," ImmunityBio founder and Executive Chairman Patrick Soon-Shiong, M.D., told CBS News.
The ImmunityBio researchers believe they may be able to create long-term protection by generating both antibodies and killer T cells.
Copyright © 2021 HealthDay. All rights reserved.